Efficacy and Safety to Evaluate Relugolix with Heavy Menstrual Bleeding Associated with Uterine Fibroids

Mise à jour : Il y a 4 ans
Référence : EUCTR2016-005113-50

Femme Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

•To determine the benefit of relugolix 40 mg once daily co-administered with low dose estradiol and norethindrone acetate compared with placebo for 24 weeks on heavy menstrual bleeding associated with uterine fibroids.


Critère d'inclusion

  • heavy menstrual bleeding associated with uterine fibroids

Liens